BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $300
آبفي
AbbVie, Inc. ABBV | 0.00 |
BMO Capital analyst Evan David Seigerman maintains AbbVie (NYSE:
ABBV) with a Outperform and raises the price target from $258 to $300.
BMO Capital Maintains Outperform on AbbVie, Raises Price Target to $300
AbbVie, Inc. ABBV | 0.00 |